Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: Clinical evidence for and against the combination

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 3, 2008, Pages 377-386

  Fares, Ramez R ^a   Lansing, Lawrence S ^a   Gallati, Christine A ^a   Mousa, Shaker A ^a,b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Acute coronary syndrome; Antiplatdet; Aspirin; Clopidogrel; Coronary artery bypass grafting; Myocardial infarction; Percutaneous coronary intervention; Peripheral artery disease; Stent; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; PARACETAMOL; PLACEBO; PRASUGREL; PYRIDINE DERIVATIVE; TICAGRELOR; DRUG DERIVATIVE; TICLOPIDINE;

ACUTE HEART INFARCTION; BLEEDING; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; DRUG CHOICE; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; EVIDENCE BASED MEDICINE; HEALTH CARE NEED; HEART REINFARCTION; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; MONOTHERAPY; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE; CARDIOVASCULAR DISEASE; DRUG COMBINATION; HEART INFARCTION;

ASPIRIN; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CORONARY DISEASE; DRUG THERAPY, COMBINATION; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 39049114716     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.3.377     Document Type: Review

References (50)

1. Jamieson DG, Parekh A, Exekowitz MD. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparison between antiplatelet agents. J Cardiovasc Pharmacol Ther 2005; 10: 153-61
2. Antiplatelet Trialist' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: prevention of death myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106
3. Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986;315:983-9
4. Fuster V, Steele PM, Chesebro JH. Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. J Am Coll Cardiol 1985;5:175B-184B
5. Hamm CW, Bliefield W, Kupper W, Lorenz RL, Weber PC, Wober W. Biochemical evidence of platelet activation in patients with persistent unstable angina. J Am Coll Cardiol 1987; 10:998-1004
6. Mousa SA, Bennett JS. Platelets in health and disease: platelet GPIIb/ IIIa structure and function: recent advances in antiplatelet therapy. Drugs Future 1996;21:1141-54
7. Mousa SA, Guigliano R. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond. In: Sasahara AA, editor. New Therapeutic Agents in Thrombosis New York. Marcel Dekker, 2003. p. 341-7
8. Born GV, Gorog P, Begent NA. The biologic background to some therapeutic uses of aspirin. Am J Med 1983;74:2-9
9. Mousa SA. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond. Curr Pharm. Design 2003;9:2317-22
10. Hart RH. Aspirin wars: the optimal dose of aspirin to prevent stroke. Stroke 1996;27:585-7
11. Hennekens CH, Sechenova O. Dose of aspirin in the treatment and prevention of cardiovascular disease. current and future directions. J Cardiovasc Pharmacol Ther 2006; 11:170-6
12. Haynes RB, Sandler RS, Larson EB, Pater JL, Yqatsu FM. A critical appraisal of ticlopidine, a new antiplatelet agent: effectiveness and clinical indications for prophylaxis of atherosclerotic events. Arch Intern Med 1992; 152:1376-80
13. Love BB, Biller J, Gent M. Adverse hematological effects of ticlopidine: prevention, recognition and management. Drug Saf Int J Med Toxicol Drug Exp 1998;9:89-98
14. Creager MA. Results of the CAPRIE trial: efficacy and safery of dopidogrel. Clopidogrel versus aspirin in patients at risk of ischemic events. Vasc Med 1998;3:257-60
15. Moussa I, Oetgen M, Roubin G, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999;99:2364-6
16. Hankey GJ, Sudlow CL, Dunbabin DW. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev 2000;2:CD001246
17. Bednar MM, Quilley J, Russell SR, et al. The effect of oral antiplatelet agents on time plasminogen activator-mediated thrombolysis in a rabbit model of thromboembolic stroke. Neurosurgery 1996;39:352-9
18. Nicolau DP, Tessier PR, Nightingale CH. Beneficial effect of combination antiplatelet therapy on the development of experimental Staphylococcus aureus endocarditis. Inc J Antimicrob Agents 1999;11:159-61
19. Lenz TL, Hilleman DE. Aggrenox: a fixed-dose combination of aspirin and dipyridamole. Ann Pharmacother 2000;34:1283-90
20. Mousa SA Antiplatelet therapies: recent advances in the development of platelet glycoprotein IIb/IIIa antagonists, Curr Interv Cardiol Rep 1999;1.-243-52
21. Mousa SA. Antiplatelet therapies: from aspirin to GPIIb/IIIa-receptor antagonists and beyond. Drug Discov Today 1999;4:552-61
22. Pytela R, Pierschbacher MS, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of RGD specific adhesion receptors. Science 1986;231:1559-62
23. Philips DR, Charo IF, Scarborough RM. GPIIb/IIIa: the responsive integrin. Cell 1991;65:359-62
24. Epic Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61
25. Hayes R, Chesebro JH, Fuster V, et al. Antithrombotic effects of abciximab. Am J Cardiol 2000;85:1167-72
26. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/ IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000;35:915-21
27. Lincoff AM, Califf RM, Van De Werf F, et al. Global Use of Strategies To Open coronary arteries investigators (GUSTO): Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs. conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA 2002;288:2130-5
28. Januzzi JL Jr. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation 2002;105:2361-6
29. Fitchett DH, Langer A, Armstrong PW, Tan M, Mendelsohn A, Goodman SG; Interact Trial Long-term Follow-up Investigators. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide: long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. Am Heart J 2006;151:373-9
30. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50(7):e1-e157
31. Steinhubl SR, Berger PB, Mann JT III, et al.; Credo Investigators. Clopidogrel for the reduction of events during observation: early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20
32. Classics Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after comnary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-9
33. Rothwell PM. Lessons from MATCH for future randomized trials in the secondary prevention of stroke. Lancet 2004;364:305-7
34. Payne DA, Jones CI, Hayes PD, et al. Benefidal effects of clopidogrel combined with aspirin in reducing cerebral emboli in patients undergoing carotid endarterectomy, Circulation 2004;109:1476-81
35. Hirsh J, Bhatt DL. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch Intern Med 2004;164:2106-10
36. Caprie Investigators. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events. Lancet 1996;348:1329-39
37. Cadroy Y, Bossavy JP, Thalamas C, Sagnard L, Sakariassen K, Boneu B. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000;101:2823-8
38. Coma-Canella I, Velasco A, Castano S. Prevalence of aspirin resistance measured by PFA-100. Int J Cardiol 2005;101(1):71-6
39. Wiviott SD, Braunwald E, McCabe CH, et al. The TRITON-TIMI 38 investigators prasugrel versus clopidogrel in patients with acute coronary syndmm. N Engl J Med 2007;357:2001-15
40. Angliolillo DJ, Shoemaker SB, Desai B, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007;115(6):708-16
41. Spertus JA. Kettelkamp, R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry Circulation 2006;113(24):2803-9
42. Smith SC, Feldman TE, Hirshfeld JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006;47(1):e1-121
43. Sabatine MS, Clarity-Timi Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89
44. Chen ZM, Jiang LX, Chen YP, et al.; COMMIT (Clopidogrel and Memprolol in Myocardial Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005;366:1607-21
45. Bhatt DL, Charisma Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-11
46. Mehra SR, Yusuf S, Peters RJ, et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention. Lancet 2001;358:527-33
47. Mehra SR, Yusuf S, Peters RJ, et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358(9281):527-33
48. Diener HC, Bogousslavsky J, Brass LM, et al. Match Investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients: randomized, double-blind, placebo-controlled trial. Lancet 2004;364:331-7
49. Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 2005; 111:2233-40
50. Storey RF, Husted S, Harrington RA. et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50(19):1852-6